Core Viewpoint - The recent trend of high-performing funds implementing "purchase limits" reflects a shift from scale-oriented strategies to investor return-oriented strategies, aimed at protecting existing fund holders' interests amidst a hot market [1][3]. Group 1: Fund Purchase Limits - Several high-performing funds have recently announced limits on large purchases, including the Caizhong Securities Asset Management's Digital Economy Mixed Fund, which has a return rate of 56.37% year-to-date as of August 18 [1]. - The Great Wall Pharmaceutical Industry Selected Mixed Fund and the CCB Flexible Allocation Mixed Fund have also set purchase limits, with year-to-date return rates of 135.09% and 49.74%, respectively [2]. - The招商成长量化选股 fund has implemented its second purchase limit this year, with a return rate of 29.55% as of August 18 [2]. Group 2: Reasons for Purchase Limits - Fund managers indicate that limiting purchases is necessary to protect performance, as large inflows at high net asset values can dilute returns and lead to inefficient cash management [2][3]. - Controlling fund size is crucial to avoid operational constraints on portfolio adjustments, especially when the fund size exceeds the manager's capability, which could lead to significant net asset value fluctuations [3]. Group 3: Market Focus and Alternatives - The limited funds primarily focus on popular sectors such as innovative pharmaceuticals, technology, and military industries, which are currently crowded, suggesting that now may not be the optimal time to invest [3]. - Fund companies are exploring other niche sectors and offering products like "fixed income plus" and FOFs to provide investors with a balanced selection [3][4]. - There is a growing interest in "fixed income plus" products and FOFs, with over 90% of FOFs achieving positive returns this year, making them an attractive option for investors seeking stable returns [4].

Core Insights - Publicly offered Fund of Funds (FOF) has achieved its best performance in five years, driven by heavy investments in equity funds, particularly in the pharmaceutical and technology sectors [1] - The shift from bond funds to equity funds has become a new growth highlight for publicly offered FOFs, with the best-performing FOF product yielding 34.28% year-to-date [1] - Over 90% of all FOFs in the market have reported positive returns this year, with the top 10 FOFs heavily investing in high-volatility equity funds while reducing allocations to bond funds and conservative balanced funds [1]

Core Insights - Publicly offered funds of funds (FOFs) have achieved their best performance in five years, primarily due to heavy investments in equity funds, particularly in the pharmaceutical and technology sectors [1] - The shift from bond funds to equity funds has become a new growth highlight for public FOFs, with over 90% of FOFs showing positive returns this year [1] - The top 10 FOFs in the market have significantly increased their allocations to high-volatility equity funds while reducing their investments in bond funds and conservative balanced funds [1] Performance Metrics - The best-performing FOF product has recorded a return of 34.28% year-to-date, a stark contrast to the best return of only 0.29% in the 2022 fiscal year [1] - The overall market performance indicates a strong recovery and positive sentiment towards equity investments among FOFs [1]